Idiopathic Pulmonary FibrosisNCT07048652
Evaluating the Diagnostic Performance of (HRCT) in IPD Fibrosis in Suspected Cases
An observational study of Idiopathic Pulmonary Fibrosis, run by Superior University at 1 site in Pakistan.
Trial summary
This will be a cross-sectional descriptive study aimed at evaluating the role of high-resolution computed tomography (HRCT) in diagnosing Idiopathic Pulmonary Fibrosis (IPF). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Idiopathic Pulmonary Fibrosis
- What is being tested?
- High-Resolution Computed Tomography
- How many people
- 68 participants
- Where
- 1 sitePakistan
- Study dates
- 17 Mar 2025to 28 Feb 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Idiopathic Pulmonary Fibrosis (IPF): IPF is defined as a chronic, progressive fibrotic interstitial lung disease diagnosed based on clinical evaluation, exclusion of other potential causes, and characteristic radiological findings on high-resolution CT (HRCT).
Who may be able to join
- Patients aged 18 years and above.
- Patients clinically suspected of having IPF.
- Patients referred for HRCT examination.
- Patients who provide informed consent to participate in the study.
Who cannot join
- Patients with a known diagnosis of other interstitial lung diseases.
- Patients with comorbid conditions that could mimic IPF.
- Patients who are pregnant.
- Patients with incomplete medical records or imaging studies
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluating the Diagnostic Performance of High-Resolution Computed Tomography (HRCT) in Detecting Idiopathic Pulmonary Fibrosis (IPF) in Suspected Cases
This will be a cross-sectional descriptive study aimed at evaluating the role of high-resolution computed tomography (HRCT) in diagnosing Idiopathic Pulmonary Fibrosis (IPF).
- Conditions
- Idiopathic Pulmonary Fibrosis
- Being tested
- High-Resolution Computed Tomography
- Medical subject headings
- Idiopathic Pulmonary Fibrosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
High-Resolution Computed TomographyDiagnostic test
High-resolution computed tomography (HRCT) plays a crucial role in diagnosing and managing Idiopathic Pulmonary Fibrosis (IPF). It helps identify the characteristic pattern of IPF, known as Usual Interstitial Pneumonia (UIP), and can sometimes obviate the need for lung biopsy.
What is being measured
The primary outcome is the main question the study is designed to answer.
high-resolution computed tomography (HRCT)
Idiopathic Pulmonary Fibrosis (IPF) high-resolution computed tomography (HRCT) scans are crucial for diagnosis and assessment of disease severity. HRCT findings typically show a reticular pattern with traction bronchiectasis and honeycombing, predominantly in the subpleural and basal regions of the lungs
Measured: 12 Months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jul 2025
- Study start17 Mar 2025
- Primary completion1 Sep 2025 (estimated)
- Study completion28 Feb 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Idiopathic Pulmonary FibrosisStudies of the same condition, open and under way.
- More trials run by Superior UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 68 participants (actual)
Sponsor and investigators
- Lead sponsor
- Superior University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Muhammad Naveed Babur, Superior University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07048652
- Sponsor's protocol ID
- MSAHSW/Batch-Fall23/905
- Status last verified
- Jun 2025
- First submitted
- 24 Jun 2025
- Last updated
- 2 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating the Diagnostic Performance of High-Resolution Computed Tomography (HRCT) in Detecting Idiopathic Pulmonary Fibrosis (IPF) in Suspected Cases
- ClinicalTrials.gov ID
- NCT07048652
- Acronym / sponsor ID
- MSAHSW/Batch-Fall23/905
- Conditions
- Idiopathic Pulmonary Fibrosis
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 68 participants (actual)
- Lead sponsor
- Superior UniversityUniversity, hospital or other
- Study start
- 17 Mar 2025 (actual)
- Primary completion
- 1 Sep 2025 (estimated)
- Study completion
- 28 Feb 2026 (estimated)
- First posted
- 2 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This will be a cross-sectional descriptive study aimed at evaluating the role of high-resolution computed tomography (HRCT) in diagnosing Idiopathic Pulmonary Fibrosis (IPF).
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Idiopathic Pulmonary Fibrosis (IPF): IPF is defined as a chronic, progressive fibrotic interstitial lung disease diagnosed based on clinical evaluation, exclusion of other potential causes, and characteristic radiological findings on high-resolution CT (HRCT).
Key inclusion criteria (4 listed)
- Patients aged 18 years and above.
- Patients clinically suspected of having IPF.
- Patients referred for HRCT examination.
- Patients who provide informed consent to participate in the study.
Key exclusion criteria (4 listed)
- Patients with a known diagnosis of other interstitial lung diseases.
- Patients with comorbid conditions that could mimic IPF.
- Patients who are pregnant.
- Patients with incomplete medical records or imaging studies
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| High-Resolution Computed TomographyHigh-resolution computed tomography (HRCT) plays a crucial role in diagnosing and managing Idiopathic Pulmonary Fibrosis (IPF). It helps identify the characteristic pattern of IPF, known as Usual Interstitial Pneumonia (UIP), and can sometimes obviate the need for lung biopsy. | Diagnostic test | – |
Primary outcome
high-resolution computed tomography (HRCT)
Time frame: 12 Months
Idiopathic Pulmonary Fibrosis (IPF) high-resolution computed tomography (HRCT) scans are crucial for diagnosis and assessment of disease severity. HRCT findings typically show a reticular pattern with traction bronchiectasis and honeycombing, predominantly in the subpleural and basal regions of the lungs
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2025.
- Individual participant dataSharing planned: No
Related trials for Idiopathic Pulmonary Fibrosis
RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
RecruitingPhase 2
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
RecruitingObservational study
Real-world Study of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
RecruitingPhase 2
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)
Not yet recruitingPhase 2
A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Idiopathic Pulmonary Fibrosis, run by Superior University at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 2 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
high-resolution computed tomography (HRCT) (time frame: 12 Months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2025.